What not to do when choosing a CRO partner.
There are five common mistakes pharmaceutical, biotech, and medical device companies make when selecting a CRO to conduct a clinical study. You want a real partnership with your CRO based on facts versus perception. Making any one of the following five mistakes could have a negative impact on your clinical study.
Brenda Reese, RN
Going with a company you've always used "just because"
Pharmaceutical, biotech, and medical device companies face new competitive, regulatory, and economic challenges. Instead of automatically assigning new studies to the CRO you've always used, try a new approach. If you're looking for a different result and you're using the same CRO, it's time to try something new. The best CROs will welcome the challenge of addressing how they can help you conduct a faster, safer, compliant clinical study.
Going with a big name CRO because it is a safe choice
When it comes to choosing a CRO, size matters. Small to mid-sized sponsors might think it's a prudent decision to award their study to a large CRO because of the resources available to them. However, a small sponsor company is unlikely to get a large CRO's "A Team" because most large CROs assign their top people to their largest clients."
Mistaking therapeutic experience with study management expertise
Sponsors want CROs with relevant experience in their indications, but therapeutic experience does not guarantee study management expertise and high quality data delivered. Avoid the pitfall of putting therapeutic experience above study management expertise or past success in other clinical studies. A good study manager will deliver a successful study with or without the therapeutic experience.
Choosing a CRO based on the lowest bid
We get what we pay for. Going with the lowest bid can lead to numerous changes of scope, which can blow up your budget. Make sure the CRO bids your project thoroughly, including all aspects of running a study. Ask the CRO to anticipate changes to the number of sites and study design and have them provide sample cost estimates in the proposal. Most CROs will just provide an hourly rate. An hourly rate needs to include an estimate of the hours required to complete the task. Most studies will have changes and knowing some of them up front will save you money down the road. A good CRO will plan for changes of scope and include the sample costs in the original bid.
Getting caught in a bait-and-switch
Choose the CRO that will staff the best team for your study. Every CRO is likely to propose its best team for your study, but will you really get them? Months can pass between awarding and beginning a study. Do not base your decision on CVs and study personnel submitted during the bidding phase because you have no control over whether those submitted will still be employed at the CRO or available for your study when it begins. Ask for the track record of the study manager assigned to your project. How many studies have they started and completed in the past two years?
Brenda Reese, RN is Executive Director of West Coast Operations at DSP Clinical Research email: brenda@dspclinical.com
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.